6533b856fe1ef96bd12b248a
RESEARCH PRODUCT
A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
Bruno MartinoDaniel B. LipkaThomas KindlerSuddhasatta AcharyyaEibhlin ConneallyVincent RibragFlorence BinlichTracy LiuAlessandro M. VannucchiFrancesco PassamontiFlorian H. HeidelSong MuClaire N. HarrisonAmjad HayatJean-jacques Kiladjiansubject
Cancer ResearchRuxolitinibPathologymedicine.medical_specialtybusiness.industryBone marrow fibrosismedicine.diseasechemistry.chemical_compoundDose findingOncologychemistryPanobinostatCancer researchMedicineIn patientbusinessJanus kinaseMyelofibrosisMyeloproliferative neoplasmmedicine.drugdescription
7022^ Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by dysregulation of the Janus kinase (JAK) pathway resulting in bone marrow fibrosis, splenomegaly, and debilitat...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |